Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios Bekaii‐Saab(Mayo Clinic Hospital), Fang‐Shu Ou(Mayo Clinic in Florida), Daniel H. Ahn(Mayo Clinic Hospital), Patrick M. Boland(Roswell Park Comprehensive Cancer Center), Kristen K. Ciombor(Vanderbilt University), Erica N. Heying(Mayo Clinic in Florida), Travis Dockter(Mayo Clinic in Florida), Nisha L. Jacobs(Minnesota Oncology), Boris Pasche(Atrium Health Wake Forest Baptist), James M. Cleary(Dana-Farber Cancer Institute), Jeffrey P. Meyers(Mayo Clinic in Florida), Rodwige J. Desnoyers(Atrium Health Wake Forest Baptist), Jeannine S. McCune(Fred Hutch Cancer Center), Katrina S. Pedersen(Washington University in St. Louis), Afsaneh Barzi(University of Southern California), E. Gabriela Chiorean(University of Washington), Jeffrey A. Sloan(Mayo Clinic in Florida), Mario E. Lacouture(Memorial Sloan Kettering Cancer Center), Heinz‐Josef Lenz(University of Southern California), Axel Grothey(West Cancer Center)
Cited by 283Open Access